Seattle Genetics (NASDAQ: [[ticker:SGEN]]) said today that it has gotten an additional undisclosed fee from its partner, Cambridge, MA-based Millennium: The Takeda Oncology Company, to expand a collaboration that seeks to develop “empowered antibody” drugs for cancer. Millennium first gained access to Seattle Genetics’ technology, which links antibodies to toxins that make them more potent, in April 2009. Now Millennium is expanding its usage of the technology, from one biological target found on solid tumors, to two. The companies are also partners on brentuximab vedotin, which Seattle Genetics hopes will become its first FDA approved product for cancer later this year.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
